OSBON MEDICALS LIMITEDActive

Company number 08414384Private limited companyIncorporated 2013

Key figures

£1,227,817+10.3%
Net assets 2024/25
+25.5%
Average annual growth 2019/20–2024/25
0500 k1 m1.5 m2019/202020/212021/222022/232023/242024/25

Like most small UK companies, OSBON MEDICALS LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2024/25
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
02.5 m5 m7.5 m2019/202020/212021/222022/232023/242024/25
Filed accounts2019/20–2024/25
2020/212021/222022/232023/242024/25
Cash at bank and in hand192,83957,81855,52150,64058,234
Total assets6,362,7226,418,4396,482,7676,239,7246,299,526
Total liabilities5,802,5735,533,5555,459,5915,126,3145,071,709
Net assets / total equity560,149884,8841,023,1761,113,4101,227,817
Average number of employees1316151524

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Summary: OSBON MEDICALS LIMITED

Company

OSBON MEDICALS LIMITED is a private limited company registered with Companies House under company number 08414384. It was incorporated on 21 Feb 2013. Its status is active. The registered office is in London (E15). Its nature of business (SIC 2007) is dispensing chemist in specialised stores (47730).

Accounts

The latest accounts in the database are for 2024/25 (period ending 31 Aug 2025); the company files abridged accounts (unaudited). Net assets were £1,227,817, up 10.3% on the previous year. Cash at bank and in hand was £58,234. Total assets were £6,299,526 and total liabilities £5,071,709. The company had an average of 24 employees. Figures are available for 6 financial years (2019/20–2024/25).

Control and charges

2 persons with significant control are registered. 2 of 11 registered charges are outstanding.

Filing deadlines

The next accounts are due by 31 May 2027. The next confirmation statement is due by 15 Nov 2026.